Ademi LLP said it is investigating potential securities fraud claims against Procept BioRobotics, focusing on whether the company made inaccurate statements about its financial reporting, business operations, and prospects. The probe centers on disclosures related to sales practices and inventory for disposable handpieces used with its aquablation technology, after the company reported quarterly revenue below forecasts and issued 2026 sales guidance below expectations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602261655PR_NEWS_USPR_____CG97147) on February 26, 2026, and is solely responsible for the information contained therein.
Comments